ArticleHereditas2025
HOXB13 affects the cancer stem cell characteristics of nasopharyngeal carcinoma by regulating the Wnt/β-catenin/SOX2 pathway.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RBM4 Promotes Nasopharyngeal Carcinoma Growth and Metastasis by Stabilizing HOXB13 mRNA.Cell biochemistry and biophysics · 2026Article
- HOX gene dysregulation in head and neck squamous cell carcinoma: mechanisms, clinical relevance, and future perspectives.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHOXB13 has been shown to act as a tumor promoter in various malignancies; however, its role in nasopharyngeal carcinoma (NPC) remains unexplored. This study aimed to investigate the function of HOXB13 in NPC and elucidate its underlying mechanism to identify novel targets for NPC diagnosis and therapy.
methodsHOXB13 expression in NPC was examined through bioinformatic analyses of the TCGA and GEO databases, and the findings were validated using molecular biology techniques. After the transfection of NPC cell lines with siRNA targeting HOXB13 (si-HOXB13), the effects of HOXB13 knockdown on cell proliferation, migration, invasion, and stemness were evaluated. Expression levels of Wnt/β-catenin/SOX2 pathway-related proteins were assessed. In vivo, NPC cells transfected with sh-HOXB13 were injected into nude mice, after which tumor volume and mass were measured, and lung metastases were analyzed using hematoxylin and eosin (H&E) staining.
resultsHOXB13 knockdown significantly reduced NPC cell viability, suppressed clonogenicity and invasiveness, increased scratch width in wound healing assays, and decreased sphere formation and the proportion of CD133
conclusionThis study demonstrates that HOXB13 facilitates the malignant progression of NPC by regulating the Wnt/β-catenin/SOX2 signaling pathway, suggesting HOXB13 as a potential therapeutic and diagnostic target for NPC, thereby offering a new strategy to improve patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.